Judith Jackson
Family · Columbus, INNPI 1871961250
Payments from drug & device makers
Across 179 payments — averaging $59.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Novo Nordisk$161
- Pfizer$146
- Lilly USA, LLC$117
- Boehringer Ingelheim$82
- Antares Pharma, Inc.$71
- plus $772 from 26 others
What the payments were for
- Speaking & faculty fees$8,17577%
- Travel & lodging$1051%
- Food & beverage$2,35922%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $9,304 |
| Novo Nordisk | 10 | $161 |
| Pfizer | 8 | $146 |
| Lilly USA, LLC | 7 | $117 |
| Boehringer Ingelheim | 4 | $82 |
| Antares Pharma, Inc. | 5 | $71 |
| Lundbeck LLC | 4 | $69 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Insulet Corporation | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Sanofi-aventis U.S. LLC | 1 | $47 |
| Exact Sciences | 2 | $44 |
| Almatica Pharma LLC | 2 | $40 |
| Bayer | 2 | $37 |
| Abbott | 2 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Novartis | 1 | $23 |
| Corium, LLC | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| GRT US Holding, Inc. | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| GSK | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$8,175
How this compares
$10,653 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 60 | $83,206 |
| OzempicSemaglutide | 32 | $49,847 |
| JardianceEmpagliflozin | 30 | $37,920 |
| TrulicityDulaglutide | 24 | $35,923 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $25,840 |
| VraylarCariprazine Hcl | 17 | $25,583 |
| Teriparatide | 11 | $21,125 |
| RexultiBrexpiprazole | 11 | $15,875 |
| LinzessLinaclotide | 18 | $15,061 |
| Spiriva RespimatTiotropium Bromide | 18 | $12,644 |
| Emgality PenGalcanezumab-Gnlm | 13 | $9,729 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $5,788 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 82 | $2,930 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,792 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $2,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $117 | $119,12984 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $82 | $50,56448 claims |
| Novo NordiskOzempic | $161 | $49,84732 claims |
| AbbVieVraylar, Linzess | $9,304 | $40,64435 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $16 | $31,62852 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $49 | $15,87511 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $62981 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Columbus
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.